) Inc. should have been 69.3%, not 84.8%. This change, however, does not affect the company's ranking in the return-on-equity category or the overall list. "Drooling over Heinz?" (Inside Wall Street, June 30) should have said that Bear, Stearns & Co. analyst Terry Bivens did not lower his fiscal 2004 earnings estimate to $2.02 a share for H.J. Heinz (HNZ
) & Co. Bivens retained his forecast of $2.15 a share. H.J. Heinz spokesman Ted Smith also argues that Heinz has strong earnings and sales targets -- 8% to 10% for earnings and 3% to 4% for sales -- contrary to what analysts say. "Schering's Dr. Feelbetter?" (People, June 23) incorrectly stated 2002 revenues for the drug Detrol. The correct figure is $757 million.